2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Checkpoint Inhibitor, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, Translational Research, MPN, CML, CMML, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly, Animal Model
PAPER

5503 Characterization of a novel KIT mutant model of systemic mastocytosis

Amara Pang, BS, Hanqian Carlson, PhD2, Shawn Shrestha3, Samantha Tauchmann, PhD4, Lucie Darmusey, PhD5, Nana Adjoa Dankyi, MBChB, PhD6, Anna Bagley, BS7, Christopher Ryder, MD PhD8, Somedeb Ball, MD9, Michael R. Savona, MD10, Eric Padron, MD11, Theodore Paul Braun, MD PhD12, Julia Maxson, PhD13
1 Knight Cancer Institute, Portland, Oregon, United States
2 Knight Cancer Institute, Portland, Oregon, United States
3 Knight Cancer Institute, Portland, Oregon, United States
4 Knight Cancer Institute, Portland, Oregon, United States
5 Knight Cancer Institute, Portland, Oregon, United States
6 H Lee Moffitt Cancer Center, Tampa, Florida, United States
7 Knight Cancer Institute, Portland, Oregon, United States
8 H Lee Moffitt Cancer Center, Tampa, Florida, United States
9 Vanderbilt Ingram Cancer Center, Nashville, Tennessee, United States
10 Vanderbilt Ingram Cancer Center, Nashville, Tennessee, United States
11 H Lee Moffitt Cancer Center, Tampa, Florida, United States
12 Oregon Health & Science University, Portland, Oregon, United States
13 Oregon Health & Science University, Portland, Oregon, United States

Systemic mastocytosis (SM) is a hematologic neoplasm characterized by the abnormal accumulation and hyperreactivity of mast cells in tissues. Over 95% of cases are driven by an activating mutation (D816V) in the KIT tyrosine kinase receptor, causing ligand-independent signaling and uncontrolled mast cell proliferation. Disease severity spans a spectrum: patients with advanced SM (AdvSM) present with a high mast cell burden and organ damage (e.g., bone marrow and hepatic failure), while patients with indolent SM (ISM) lack organ dysfunction but experience chronic multisystemic disease with high symptom burden and impaired quality of life. Although tyrosine kinase inhibitors have shown clinical efficacy in reducing mast cell burden in both AdvSM and ISM, these treatments are not generally curative.

 The development of additional therapies is limited by our understanding of KIT mutation cellular origin and how it specifies mast cell expansion. To identify which hematopoietic cells harbor KITD816V, we harnessed scDNA-sequencing to characterize mutant KIT in AdvSM patient samples. Consistent with previously published work, our data show that KITD816V is multi-lineage and present in primitive cells, such as hematopoietic stem and progenitor cells (HSPCs), even in cases where the variant allele frequency is only detectable by ddPCR. Despite this multi-lineage distribution, how mutant KIT initiates SM is poorly understood. Thus, defining how KITD816V dictates progenitor cell behavior and cell lineage differentiation during SM disease initiation and development could uncover novel therapeutic vulnerabilities. However, our ability to define the role of KITD816V in mast cell fate is limited by a paucity of models that accurately recapitulate human disease.

To address this challenge, we generated a novel inducible mouse model with heterozygous expression of KitD814V (equivalent to human D816V) in the endogenous allele. Given that KIT mutations arise in HSPCs, we used an HSC-SCL-CreERT driver to induce the mutant allele specifically in this cell compartment. To assess mast cell burden, we measured serum tryptase levels, a protein secreted by mast cells and a key biomarker of SM. KitWT/D814V mice developed a 20-fold increase in serum tryptase, along with increased terminally differentiated mast cells (KIT+/FCRE1A+) in the skin, bone marrow, liver, and spleen. Histological analysis revealed granulocytic hyperplasia in the bone marrow, extramedullary hematopoiesis in the liver and spleen, and mast cell aggregates in the liver and the dermal layer of the skin. Mutant mice also developed hepatosplenomegaly. Ultimately, KitWT/D814V mice developed a uniformly lethal phenotype with 100% disease penetrance. The median survival was 21 days post-induction, primarily driven by organ dysfunction secondary to mast cell infiltration. Overall, these data demonstrate that KitWT/D814V in HSPCs is sufficient to recapitulate key features of SM, serving as a novel model to advance the field.

Strikingly, KitWT/D814V mice had significantly fewer bone marrow long and short-term hematopoietic stem cells (HSCs) than controls, along with evidence of mast cell expansion. To evaluate stem cell function, we plated marrow in colony-forming assays and found that KitD814V reduced colony formation relative to controls. This defect persisted upon serial replating, indicating that KitD814V impaired self-renewal. We also detected an expansion of the mast cell progenitor population in KitWT/D814V bone marrow, suggesting that apical KitD814V mutations bias hematopoietic output toward the mast cell lineage. Together, our data suggest that KitD814V drives SM not simply by expanding the terminal mast cell compartment but by diverting HSPC fate away from stem cell maintenance toward the mast cell lineage.

Our novel physiologically relevant KitWT/D814V preclinical mouse model provides the field with an in vivo system to interrogate the initiation and development of SM. This inducible system offers a tractable platform to dissect the molecular basis of this lineage bias and its effect on disease severity in SM.

Amara Pang, BS: No relevant conflicts of interest to declare.